Shares of Tilray (NASDAQ: TLRY) fell 14% on Thursday following the cannabis company's fourth-quarter results.
Tilray's revenue rose 20.5% year over year to $56.6 million. A 49% jump in Canadian adult-use sales and a 191% surge in international medical marijuana sales fueled the gains, which were partially offset by an 18% decline in hemp revenue.
Tilray's stock declined sharply on Thursday. Image source: Getty Images.
Source Fool.com